Chronic Renal Failure
Conditions
Brief summary
study the effect of omega 3fatty acids on the vascular calcification biomarkers Fetuin -A and Osteoprotegerin (OPG) in dialysis patients.
Detailed description
2-All Participants agreed to take part in this clinical research and provide informed consent. 3-Patients undergo both undergo hemodialysis (HD) will be enrolled from dialysis unit in al Moussa Hospital Alexandria. 4-Serum samples will be collected for measuring the biomarkers. 5-Our design is randomized, controlled, open-intervention study. 6- All enrolled patients will be divided into 2 groups, Group 1 will be 40 patients that will take omega 3fatty acids and Group 2 will be 20 patients will not take omega 3 fatty acids. 7-All patients will be followed up during 6 months' period. 8-Statsicial tests appropriate to the study design will be conducted to evaluate the significance of the results. 9-Measuring outcome: the primary outcome is the increase of the serum levels of the vascular calcification biomarkers after 6months. 10-Results, conclusions, discussion and recommendations will be given. Inclusion criteria: * 60 hemodialysis patients, (20-80) years old. * Enrolled HD patients received regular HD 3 times weekly (on chronic maintenance for at least 6months). Exclusion Criteria: People with active infections (fever or any evidence of infections), known malignancy, connective tissue disorders, immunosuppressive therapy, and inflammatory diseases, current use of warfarin ,history of fish oil/omega 3 allergies were excluded. Methodology: * Feutin-A and Osteoprotegrin (OPG) will be determined by ELISA. * Serum lipid levels, phosphorus, calcium, Parathormone (i-PTH), alkaline phosphatase, albumin and creatine levels. * BMI
Interventions
DIETARY_SUPPLEMENTOmega 3 fatty acids (fish oil) 1000 mg/day oral
Omega 3 fatty acids (fish oil) 1000 mg/day oral
Sponsors
Damanhour University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Intervention model description
enrolled patients will be divided into 2 groups, Group 1 will be 40 patients that will take omega 3fatty acids and Group 2 will be 20 patients served as control will not take omega 3 fatty acids.
Eligibility
Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* 60 hemodialysis patients, (20-80) years old. * Enrolled HD patients received regular HD 3 times weekly (on chronic maintenance for at least 6 months).
Exclusion criteria
* People with active infections (fever or any evidence of infections), known malignancy, connective tissue disorders, immunosuppressive therapy, and inflammatory diseases, current use of warfarin ,history of fish oil/omega 3 allergies were excluded.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Feutin-A Level | six months | vascular calcification biomarkers |
| Osteoprotegrin | six months | vascular calcification biomarkers |
Countries
Egypt
Outcome results
None listed